Abstract:1. C9orf142 is elevated in TNBC patients and its elevation predicts unfavourable clinical outcome. 2. C9orf142 augments TNBC progression through transcriptional transaction of MTBP to regulate its downstream MDM2/p53/p21 signaling axis. 3. C9orf142 promotes resistance of TNBC cells to CDK4/6 inhibitor partially depend on MTBP/MDM2/p53/p21 signaling axis. 4. Knockdown of C9orf142 inhibits TNBC progression and enhances its sensitivity to CDK4/6 inhibitor. Background Triple‐negative breast cancer (TNBC) presents the most challenging subtype of all breast cancers because of its aggressive clinical phenotypes and absence of viable therapy targets. In order to identify effective molecular targets for treating patients with TNBC, we conducted an integration analysis of our recently published TNBC dataset of quantitative proteomics and RNA‐Sequencing, and found the abnormal upregulation of chromosome 9 open reading frame 142 (C9orf142) in TNBC. However, the functional roles of C9orf142 in TNBC are unclear. Methods In vitro and in vivo functional experiments were performed to assess potential roles of C9orf142 in TNBC. Immunoblotting, real‐time quantitative polymerase chain reaction (RT‐qPCR), and immunofluorescent staining were used to investigate the expression levels of C9orf142 and its downstream molecules. The molecular mechanisms underlying C9orf142‐regulated mouse double minute 2 (MDM2)‐binding protein (MTBP) were determined by chromatin immunoprecipitation (ChIP) and dual‐luciferase reporter assays. Results In TNBC tissues and metastatic lymph nodes, we observed that C9orf142 exhibited abnormal up‐regulation, and its elevated expression was indicative of unfavorable prognosis for TNBC patients. Both in vitro and in vivo functional experiments demonstrated that C9orf142 accelerated TNBC growth and metastasis. Further mechanism exploration revealed that C9orf142 transcriptionally activated MTBP, thereby regulating its downstream MDM2/p53/p21 signaling axis and the transition of cell cycle from G1 to S phase. Functional rescue experiment demonstrated that knockdown of MTBP attenuated C9orf142‐mediated tumour growth and metastasis. Furthermore, depletion of C9orf142 remarkably increased the responsiveness of TNBC cells to CDK4/6 inhibitor abemaciclib. Conclusions Together, these findings unveil a previously unrecognized effect of C9orf142 in TNBC progression and responsiveness to CDK4/6 inhibitor, and emphasize C9orf142 as a promising intervention target for TNBC treatment.

SNRPB2 promotes triple‐negative breast cancer progression by controlling alternative splicing of MDM4 pre‐mRNA

Activation of ERβ Hijacks the Splicing Machinery to Trigger R-loop Formation in Triple-Negative Breast Cancer

DDX20 interlinking with SNRPE endows MYC-driven triple-negative breast cancer therapeutic vulnerability in a splicing-independent manner

The Potential Role of SNRPD1 Stabilized by IGF2BP2 in the Progression of Triple-Negative Breast Cancer

An in Vivo CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

NRBP2 Functions as a Tumor Suppressor and Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer

HNRNPU Promotes the Progression of Triple-Negative Breast Cancer Via RNA Transcription and Alternative Splicing Mechanisms.

The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2

RSRC2 Expression Inhibits Malignant Progression of Triple-Negative Breast Cancer by Transcriptionally Regulating SCIN Expression

Cancer-Associated MORC2-Mutant M276I Regulates an Hnrnpm-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer

Spermatid perinuclear RNA-binding protein promotes UBR5-mediated proteolysis of Dicer to accelerate triple-negative breast cancer progression

Splicing factor hnRNPA2B1 contributes to tumorigenic potential of breast cancer cells through STAT3 and ERK1/2 signaling pathway

RNA-binding Protein MSI2 Isoforms Expression and Regulation in Progression of Triple-Negative Breast Cancer

Supplementary Figure S1-9 from an in Vivo CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression

SNHG14 promotes triple‐negative breast cancer cell proliferation, invasion, and chemoresistance by regulating the ERK/MAPK signaling pathway

SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1

RBM7 deficiency promotes breast cancer metastasis by coordinating MFGE8 splicing switch and NF-kB pathway

C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple‐negative breast cancer

Functional Interaction Between the Oncogenic Kinase NEK2 and Sam68 Promotes a Splicing Program Involved in Migration and Invasion in Triple-Negative Breast Cancer

The miR-124-3p/Neuropilin-1 Axis Contributes to the Proliferation and Metastasis of Triple-Negative Breast Cancer Cells and Co-Activates the TGF-β Pathway